Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. The MINT trial ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval is ...

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...

Francisco J. Rivera Rosario is a science communications editor experienced in developing all types of science content including, scientific journal articles, infographics, medical educational videos, ...

The FDA expanded the indication of inebilizumab (Uplizna) to include generalized myasthenia gravis (gMG), Amgen announced Friday. The drug is now approved to treat gMG in adults who are ...

Background A 46-year-old woman presented to a local hospital with acute respiratory failure and a 2-year progressive history of fatigue, personality changes, increased sweating, dysphagia with ...

Mestinon (pyridostigmine) is a prescription drug used to treat myasthenia gravis. Mestinon can cause side effects that range from mild to serious, including digestive symptoms, such as diarrhea, ...

In 2004, a man from Graz, Austria, began a gruelling two-decade journey with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes muscle weakness and fatigue. Over the years, he ...

Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for IgG4-related disease in April. On Thursday, the FDA approved a key ...